Abstract

We previously reported the tumor suppressor function of Zinc-fingers and homeoboxes 2 (ZHX2) in hepatocellular carcinoma (HCC). Other studies indicate the association of increased ZHX2 expression with improved response to high dose chemotherapy in multiple myeloma. Here, we aim to test whether increased ZHX2 levels in HCC cells repress multidrug resistance 1(MDR1) expression resulting in increased sensitivity to chemotherapeutic drugs. We showed evidence that increased ZHX2 levels correlated with reduced MDR1 expression and enhanced the cytotoxicity of CDDP and ADM in different HCC cell lines. Consistently, elevated ZHX2 significantly reduced ADM efflux in HepG2 cells and greatly increased the CDDP-mediated suppression of liver tumor growth in vivo. Furthermore, immunohistochemical staining demonstrated the inverse correlation of ZHX2 and MDR1 expression in HCC tissues. Luciferase report assay showed that ZHX2 repressed the MDR1 promoter activity, while knockdown of NF-YA or mutating the NF-Y binding site eliminated this ZHX2-mediated repression of MDR1 transcription. Co-IP and ChIP assay further suggested that ZHX2 interacted with NF-YA and reduced NF-Y binding to the MDR1 promoter. Taken together, we clarify that ZHX2 represses NF-Y-mediated activation of MDR1 transcription and, in doing so, enhances the effects of chemotherapeutics in HCC cells both in vitro and in vivo.

Highlights

  • Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide with high mortality, and poor prognosis

  • Increased Zinc-fingers and homeoboxes 2 (ZHX2) levels led to reduced drug efflux and enhanced the cytotoxicity of anti-cancer drugs in hepatocellular carcinoma (HCC) cell lines

  • ZHX2 was found to repress the expression of genes that are frequently upregulated in HCC, including AFP, GPC3 and H19 [11, 12]

Read more

Summary

Introduction

Hepatocellular carcinoma (HCC) is one of the most common cancers worldwide with high mortality, and poor prognosis. A large number of therapeutic agents have been evaluated for the treatment of HCC, most have been ineffective due to the high chemoresistance, especially the multidrug resistance (MDR) of liver cancer cells [1, 2]. Accumulated data confirm the important role of MDR1 in the resistance of HCC cells against different chemodrugs, including the commonly used chemotherapeutic drugs cisplatin [cis-diamminedichloroplatinum (CDDP)] and Adriamycin (ADM)[4,5,6]. Strategies targeting MDR1 have been recognized as a potential method to restore chemotherapeutic sensitivity of cancer cells, strategies have had minimal clinical benefit [3, 7]. Understanding the regulation of MDR1 expression in HCC is essential to develop more effective treatments

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call